Stocks and InvestingStocks and Investing
Fri, June 25, 2021
Thu, June 24, 2021
Wed, June 23, 2021
Tue, June 22, 2021
Mon, June 21, 2021
Sun, June 20, 2021
Fri, June 18, 2021
Thu, June 17, 2021

Liana Moussatos Maintained (BPMC) at Buy with Decreased Target to $130 on, Jun 17th, 2021


Published on 2024-10-27 17:00:26 - WOPRAI, Liana Moussatos
  Print publication without navigation


Liana Moussatos of Wedbush, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Decreased Target from $136 to $130 on, Jun 17th, 2021.

Liana has made no other calls on BPMC in the last 4 months.



There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 3 agree with Liana's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $101 on, Friday, April 30th, 2021
  • Brad Canino of "Credit Suisse" Initiated at Hold and Held Target at $100 on, Wednesday, March 31st, 2021
  • Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $95 on, Thursday, February 18th, 2021


This is the rating of the analyst that currently disagrees with Liana


  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $110 on, Thursday, April 29th, 2021